YOLFTbeta
Dyne Therapeutics Inc

Dyne Therapeutics Inc

DYN · NASDAQ · Healthcare / Biotechnology

17.16USD+0.15 (+0.88%)

Price History

Full chart

Market Stats

Previous Close17.01
Open16.90
Day Range16.42 – 17.35
52-Week Range11.92 – 27.31
Volume1.67M
Market Cap2.99B
P/E (TTM)0.00
Forward P/E0.00
EPS-3.26
Dividend Yield0.00%
Beta1.08
50-Day Avg23.42
200-Day Avg19.73

About

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. John G. Cox M.B.A.
  • Employees289
  • Headquarters1560 Trapelo Road, Waltham, MA, United States, 02451, USA
  • Websitehttps://www.dyne-tx.com

Leadership

  • Mr. John G. Cox M.B.A.CEO, President & Director · b. 1963
  • Mr. Erick J. Lucera C.F.A., CPACFO, Principal Financial Officer & Principal Accounting Officer and Treasurer · b. 1968
  • Dr. Oxana Beskrovnaya Ph.D.Chief Innovation Officer · b. 1961
  • Ms. Johanna Friedl-NadererChief Commercial Officer · b. 1968
  • Dr. Douglas Kerr M.B.A., M.D., Ph.D.Chief Medical Officer · b. 1967
  • Dr. Axel WiestSenior VP and Head of Portfolio Strategy & Operations
  • Dr. Rajesh Manchanda Ph.D.Chief Technical Officer · b. 1967
  • Mr. James P. Bilotta M.B.A.Chief Digital & Information Officer
  • Mr. Alessandro MartuscelliChief Legal Officer
  • Ms. Lucia CelonaChief Human Resource Officer · b. 1966

Financials

Income Statement

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.10B3.55B2.47B2.32B1.58B3.00M3.00M1.47B842.00M1.37B506.00M00000000
Growth (%)-+14.37%-30.46%-5.88%-31.77%-99.81%0.00%+48766.67%-42.56%+62.23%-62.96%-100.00%-------
Cost of Revenue2.01B1.85B1.19B1.18B963.00M268.00M1.15B1.15B2.03B2.28B2.93B24.00K271.00K700.00K1.09M3.35M2.46M2.24M2.05M
Gross Profit1.09B1.70B1.27B1.14B622.00M-265.00M-1.14B321.00M-1.19B-915.00M-2.43B-24.00K-271.00K-700.00K-1.09M-3.35M-2.46M-2.24M-2.05M
Gross Margin35.13%47.79%51.62%49.16%39.24%-8833.33%-38066.67%21.90%-140.86%-66.98%-479.45%--------
Operating Expense485.00M987.00M2.11B1.15B858.00M-979.00M-824.00M639.00M-1.25B-275.00M-2.01B4.77M13.55M57.95M148.94M167.62M239.70M341.64M466.13M
Operating Income605.00M709.00M-834.00M-11.00M-236.00M714.00M-318.00M-318.00M64.00M-640.00M-412.00M-4.79M-13.83M-58.65M-150.03M-170.96M-242.16M-343.89M-468.18M
Operating Margin19.50%19.98%-33.79%-0.47%-14.89%23800.00%-10600.00%-21.69%7.60%-46.85%-81.42%--------
EBITDA830.00M902.00M-173.00M734.00M-1.57B113.00M150.00M292.00M736.00M106.00M949.00M-4.79M-14.59M-57.95M-148.20M-169.28M-233.48M-315.18M-437.97M
EBITDA Margin26.75%25.42%-7.01%31.60%-99.31%3766.67%5000.00%19.92%87.41%7.76%187.55%--------
Net Income264.00M174.00M-1.26B-234.00M-1.65B87.00M-356.00M-67.00M50.00M-1.24B76.00M-4.81M-13.54M-58.74M-149.29M-165.24M-235.94M-317.42M-446.21M
Net Income Margin8.51%4.90%-51.13%-10.07%-103.79%2900.00%-11866.67%-4.57%5.94%-90.78%15.02%--------
R&D-----------4.28M11.04M45.20M121.31M142.76M210.76M281.41M398.33M
Interest Expense384.00M427.00M415.00M363.00M357.00M097.00M67.00M546.00M625.00M616.00M5.00K290.00K396.00K742.00K2.92M006.19M
Interest Expense % of Total Revenue12.38%12.03%16.82%15.63%22.52%0.00%3233.33%4.57%64.85%45.75%121.74%--------

Balance Sheet

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets13.22B14.21B10.95B10.01B4.13B4.54B5.29B11.23B11.54B13.05B11.77B8.27M16.44M353.33M425.66M306.32M165.08M691.23M1.19B
Total Liabilities8.69B9.73B7.97B7.27B3.02B2.03B3.08B8.21B8.62B11.01B9.87B13.15M2.40M10.97M57.47M53.96M73.79M61.40M214.83M
Total Equity4.51B4.51B2.90B2.75B1.11B2.50B2.21B3.02B2.92B2.04B1.90B-4.88M14.04M342.37M368.20M252.36M91.29M629.84M972.13M
Cash328.00M693.00M471.00M291.00M396.00M348.00M843.00M1.87B505.00M1.78B365.00M8.12M14.63M300.85M200.82M172.15M121.63M435.45M893.37M
Total Debt102.00M128.00M1.61B4.57B588.00M1.42B1.99B7.11B7.29B8.98B8.43B3.38M--32.64M30.48M27.41M23.99M20.28M
Net Debt-226.00M-565.00M1.14B4.28B192.00M1.07B1.15B5.24B6.78B7.20B8.07B-4.75M-14.63M-300.85M-168.19M-141.66M-94.21M-411.46M-873.09M

Cash Flow

Currency: USD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow341.00M319.00M135.00M423.00M-20.00M-44.00M175.00M-62.00M94.00M676.00M585.00M-4.16M-11.83M-46.51M-119.56M-153.65M-188.16M-292.37M-403.21M
Investing Cash Flow-817.00M-102.00M251.00M-534.00M-254.00M348.00M474.00M-5.15B-1.19B-2.15B-2.76B-134.00K-1.65M-45.66M-137.89M87.20M83.31M-204.08M-28.75M
Financing Cash Flow433.00M148.00M-608.00M-69.00M379.00M-328.00M-154.00M5.21B-265.00M2.74B-1.30B12.42M19.99M380.69M157.82M37.39M54.32M809.89M890.31M
Capital Expenditure000333.00M242.00M098.00M0275.00M326.00M224.00M134.00K1.65M1.16M3.62M3.07M729.00K2.38M1.92M
Free Cash Flow341.00M319.00M135.00M90.00M-262.00M-44.00M77.00M-62.00M-181.00M350.00M361.00M-4.30M-13.48M-47.67M-123.18M-156.71M-188.89M-294.75M-405.13M
Dividends Paid--------23.00M22.00M22.00M--------
FCF to OCF100.00%100.00%100.00%21.28%1310.00%100.00%44.00%100.00%-192.55%51.78%61.71%103.22%113.92%102.50%103.03%102.00%100.39%100.81%100.48%
Dividend Paid to FCF---------12.71%6.29%6.09%--------

Earnings

Report DateJun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Sep 17, 2020Nov 5, 2020Mar 4, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Mar 10, 2022May 2, 2022Aug 4, 2022Nov 3, 2022Mar 2, 2023May 11, 2023Aug 3, 2023Oct 30, 2023Mar 5, 2024May 2, 2024Aug 12, 2024Nov 12, 2024Mar 3, 2025May 8, 2025Jul 28, 2025Nov 5, 2025Feb 26, 2026May 11, 2026Jul 29, 2026Nov 4, 2026
EPS Estimate-0.690.210.14-0.11-0.710.55-0.420.00-0.39-0.37-0.62-0.55-0.66-0.97-0.88-0.80-0.92-0.84-0.76-0.78-0.76-0.93-0.80-0.72-0.71-0.91-0.84-0.93-0.81-0.77-0.78-0.74-0.88
EPS Actual-1.36-0.30-1.40-1.24-1.120.31-0.35-0.39-0.31-0.64-0.50-0.58-0.83-1.00-0.69-1.01-0.80-0.74-0.78-1.08-0.99-1.09-0.81-0.70-0.96-0.88-1.05-0.97-0.76-0.73-0.73-1.08-
Surprise-97.10%-242.86%-1100.00%-1027.27%-57.75%-43.64%16.67%-20.51%-72.97%19.35%-5.45%-25.76%-3.09%21.59%-26.25%13.04%11.90%-2.63%-38.46%-30.26%-17.20%-1.25%2.78%-35.21%3.51%-25.00%-4.30%6.17%5.48%6.41%-45.95%-
Timing-------After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hours-Pre-marketAfter-hours-

Key Statistics & Ratios

Market Cap2.99B
Enterprise Value2.35B
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.19
Price / Sales0.00
Price / Book4.32
EPS-3.26
Book Value4.24
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-534.80M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-81.57%
Return on Assets-38.96%
Shares Outstanding186.75M
Shares Float186.24M
Beta1.08
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 14 analystsTarget 37.20
  • Strong Buy
    7
  • Buy
    6
  • Hold
    1

Ownership Breakdown

Institutions
103.65%
Insiders
0.24%
Retail / Other
0.00%

Top Institutional Holders

  • T. Rowe Price Investment Management,Inc.
    30.79M16.49%
  • HHG PLC
    13.65M7.31%
  • BlackRock Inc
    11.70M6.27%
  • FMR Inc
    8.91M4.77%
  • Atlas Venture Life Science Advisors, LLC
    6.80M3.64%
  • Orbis Allan Gray Ltd
    6.76M3.62%
  • State Street Corp
    6.65M3.56%
  • Vanguard Capital Management, LLC
    6.41M3.43%
  • FCPM III SERVICES BV
    4.64M2.49%
  • TCG Crossover Management, LLC
    4.62M2.47%
  • Vanguard Portfolio Management, LLC
    4.16M2.23%
  • Vestal Point Capital LP
    4.00M2.14%
  • Geode Capital Management, LLC
    3.50M1.88%

Top Fund Holders

  • T. Rowe Price Small-Cap Stock
    7.38M3.95%
  • Vanguard MStar Total Stk Mkt Idx Invest
    5.26M2.82%
  • T. Rowe Price Small-Cap Value
    4.66M2.49%
  • State Street® SPDR® S&P® Biotech ETF
    4.37M2.34%
  • T. Rowe Price Instl Small-Cap Stock
    4.02M2.15%
  • iShares Russell 2000 ETF
    3.85M2.06%
  • T. Rowe Price Capital Appreciation
    3.70M1.98%